Dogan Fidan

800 total citations
14 papers, 530 citations indexed

About

Dogan Fidan is a scholar working on Cardiology and Cardiovascular Medicine, Organic Chemistry and Pharmacology. According to data from OpenAlex, Dogan Fidan has authored 14 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 4 papers in Organic Chemistry and 4 papers in Pharmacology. Recurrent topics in Dogan Fidan's work include Synthesis of β-Lactam Compounds (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Dogan Fidan is often cited by papers focused on Synthesis of β-Lactam Compounds (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Dogan Fidan collaborates with scholars based in United Kingdom, France and Canada. Dogan Fidan's co-authors include Frederick A. Anderson, John A. Heit, Alexander T. Cohen, Sarah Garner, Simon Capewell, Julia Critchley, Martina Garau, Asja Fischer, Alec Miners and Belgin Ünal and has published in prestigious journals such as Circulation, American Journal of Public Health and Cochrane Database of Systematic Reviews.

In The Last Decade

Dogan Fidan

14 papers receiving 502 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Dogan Fidan 231 221 106 100 77 14 530
C. Suárez 370 1.6× 335 1.5× 175 1.7× 50 0.5× 13 0.2× 39 776
Craig J. Beavers 352 1.5× 90 0.4× 116 1.1× 18 0.2× 17 0.2× 54 611
Shannon W. Finks 222 1.0× 111 0.5× 98 0.9× 21 0.2× 20 0.3× 36 423
Thomas Harkins 122 0.5× 107 0.5× 38 0.4× 54 0.5× 11 0.1× 12 325
Henri Boccalon 278 1.2× 212 1.0× 191 1.8× 54 0.5× 4 0.1× 21 638
Mark Stuntz 80 0.3× 16 0.1× 99 0.9× 58 0.6× 26 0.3× 16 436
Chandrasekar Gopalakrishnan 114 0.5× 34 0.2× 59 0.6× 66 0.7× 20 0.3× 28 553
Ruslan Horblyuk 464 2.0× 271 1.2× 58 0.5× 66 0.7× 9 0.1× 41 712
Frits R. Rosendaal 100 0.4× 30 0.1× 43 0.4× 61 0.6× 31 0.4× 4 373
Khai Ping Ng 101 0.4× 28 0.1× 35 0.3× 60 0.6× 12 0.2× 14 406

Countries citing papers authored by Dogan Fidan

Since Specialization
Citations

This map shows the geographic impact of Dogan Fidan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dogan Fidan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dogan Fidan more than expected).

Fields of papers citing papers by Dogan Fidan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dogan Fidan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dogan Fidan. The network helps show where Dogan Fidan may publish in the future.

Co-authorship network of co-authors of Dogan Fidan

This figure shows the co-authorship network connecting the top 25 collaborators of Dogan Fidan. A scholar is included among the top collaborators of Dogan Fidan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dogan Fidan. Dogan Fidan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Garner, Sarah, Dogan Fidan, Maria Judd, et al.. (2017). Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2017(6). CD003831–CD003831. 15 indexed citations
2.
Karagöz, Gül, et al.. (2016). The analysis of the cost and amputation rates of hospitalized diabetic foot infection patients. International Journal of Diabetes in Developing Countries. 37(2). 201–205. 2 indexed citations
3.
Zhang, Zugui, Paul Kolm, Claudine Jurkovitz, et al.. (2009). The Risk of Cardiovascular Events in Primary Care Patients Following an Episode of Severe Hypertension. Journal of Clinical Hypertension. 11(4). 175–182. 2 indexed citations
4.
Zhao, Liping, Paul Kolm, Claudine Jurkovitz, et al.. (2009). Determining the In‐Hospital Cost of Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Journal of Interventional Cardiology. 22(3). 266–273. 15 indexed citations
5.
Bennett, Kathleen, Zubair Kabir, Michael Barry, et al.. (2008). Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010. Value in Health. 12(1). 10–15. 10 indexed citations
6.
Berg, Jenny, Dogan Fidan, & Peter Lindgren. (2008). Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Current Medical Research and Opinion. 24(7). 2089–2101. 17 indexed citations
7.
Anderson, Frederick A., et al.. (2007). Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism. American Journal of Hematology. 82(9). 777–782. 224 indexed citations
8.
Zhang, Zefeng, Paul Kolm, Wei Zhang, et al.. (2007). Abstract 3774: Cost Effectiveness Of Enoxaparin In Patients With ST-elevation Myocardial Infarction: Results From EXTRACT-TIMI 25. Circulation. 116(suppl_16). 1 indexed citations
9.
Garner, Sarah, Dogan Fidan, Maria Judd, et al.. (2005). Rofecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2010(7). CD003685–CD003685. 42 indexed citations
10.
Garner, Sarah, et al.. (2005). Rofecoxib for osteoarthritis. Cochrane Database of Systematic Reviews. 2010(1). CD005115–CD005115. 29 indexed citations
11.
Ünal, Belgin, Julia Critchley, Dogan Fidan, & Simon Capewell. (2005). Life-Years Gained From Modern Cardiological Treatments and Population Risk Factor Changes in England and Wales, 1981–2000. American Journal of Public Health. 95(1). 103–108. 62 indexed citations
12.
Miners, Alec, Martina Garau, Dogan Fidan, & Asja Fischer. (2004). Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ. 330(7482). 65–65. 65 indexed citations
13.
Garner, Sarah, Dogan Fidan, Maria Judd, et al.. (2002). Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews. CD003831–CD003831. 39 indexed citations
14.
Beecham, Jennifer, et al.. (2002). Children with severe learning disabilities: needs, services and costs. Children & Society. 16(3). 168–181. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Suárez Breakdown of academic impact, for papers by Craig J. Beavers Breakdown of academic impact, for papers by Shannon W. Finks Breakdown of academic impact, for papers by Thomas Harkins Breakdown of academic impact, for papers by Henri Boccalon Breakdown of academic impact, for papers by Mark Stuntz Breakdown of academic impact, for papers by Chandrasekar Gopalakrishnan Breakdown of academic impact, for papers by Ruslan Horblyuk Breakdown of academic impact, for papers by Frits R. Rosendaal Breakdown of academic impact, for papers by Khai Ping Ng
Rankless by CCL
2026